Showing results (471-480 of 554) with videos related to

Sort By:
Pageof 56
JCO Precision Oncology|May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsMichael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.
American Journal of Medical Genetics|February 16, 1996
A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Schizophrenia Collaborative Linkage Group (Chromosome 22)M Gill, H Vallada, D Collier, et al.
European Urology Oncology|February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair GenesRuben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2020
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate CancerMatthew P Deek, Kekoa Taparra, Dyda Dao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.
The New England Journal of Medicine|September 4, 2014
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerEmmanuel S Antonarakis, Changxue Lu, Hao Wang, et al.
The American Journal of Pathology|March 27, 2018
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate CancerMichael C Haffner, Gunes Guner, Diana Taheri, et al.
The Prostate|April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancerElisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
Pageof 56